KPV was previously not offered by telos rx. It is now offered as a compounded prescription after an online review by a licensed provider. This page explains what changed, without implying that a prescription is guaranteed.
telos rx previously did not offer KPV. It is now offered after provider review, and your provider sets the dose, form and schedule. You can read more on the KPV page.
The short version
If you came here to find out whether you can start KPV through telos rx today, the answer has changed. When this page was first written, KPV was not sold, not stocked, and not offered as part of any protocol. It is now offered as a compounded prescription, but only after a licensed provider reviews your online intake and decides it is appropriate. Approval is not guaranteed.
This is not a statement about whether KPV works or does not work. It is a statement about where telos rx's compounding program currently stands, which is a separate question from the underlying science.
What this page will and will not do
This page will tell you plainly what telos rx offers and why. It uses the true reasons rather than a vague placeholder. It will not imply that a prescription is guaranteed, or that KPV is right for everyone simply because interest is high.
Why availability and evidence are different questions
It is easy to assume that if a peptide was not offered, it must have failed some kind of test. That was not accurate here. telos rx's earlier decision not to offer KPV reflected where its internal review and the regulatory picture stood, not a conclusion that the peptide is unsafe or ineffective.
A compounding pharmacy program has to weigh several factors before adding any new peptide. Classification status, sourcing from licensed pharmacies, consistency of preparation standards, and how confidently a provider can evaluate a patient all matter. Those same factors still apply now that KPV is offered, and offering it is not a claim that the evidence is settled.
What "under review" used to mean
telos rx maintains a running review of research peptides for potential inclusion in its compounding program. KPV sat in that review for a period, which meant it was being tracked and evaluated, not queued for a release date.
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding KPV and several other peptides to the list of bulk substances that can be used in compounding. That vote was non-binding. Then, on October 28, 2026, HHS announced an interim enforcement discretion policy for six peptides, KPV included: HHS does not intend to take enforcement action against state-licensed pharmacies or licensed physicians that compound them with a valid prescription, as long as strict conditions are met, such as FDA-registered suppliers, lot-level testing and single-ingredient products. For KPV, the policy covers topical and oral forms only. It is temporary while FDA completes rulemaking, it is not FDA approval, and HHS can revisit it if safety or quality problems arise.
Key takeaway: KPV has moved from "under review" to offered after provider review. That is a change in what telos rx offers, not a guarantee that any individual will be prescribed it.
What telos rx does offer today
telos rx runs an active compounded peptide program. Alongside KPV, that includes BPC-157, PT-141, NAD+ nasal spray, and sermorelin, each sourced through partner compounding pharmacies and reviewed by a licensed provider before any prescription is issued.
These peptides are not interchangeable in a clinical sense. A provider looks at your goals and history to decide which, if any, fits.
The regulatory backdrop, briefly
Compounded medications broadly are not FDA-approved. They are prepared by licensed pharmacies under federal compounding rules that govern which substances can be compounded and under what conditions. The FDA publishes a general overview of how this works, available on its compounding questions and answers page.
Peptides like KPV sat in a gray area of this framework until the October 2026 HHS policy described above. There is real scientific interest in the molecule, documented in laboratory and animal research summarized by the National Institutes of Health. Interest and evidence are not the same as a clear regulatory pathway for pharmacy compounding. That gap is what telos rx's review process was meant to sort through.
What changed
Two things needed to shift for KPV's status to change. The first was clearer regulatory footing for compounding pharmacies, which the October 2026 HHS interim policy provided on a temporary basis. The second was telos rx's own internal review concluding that the peptide meets its standards for sourcing, dosing guidance, and provider oversight.
Both have now happened, so telos rx offers KPV after provider review. The HHS policy is temporary and can be revisited, and this page will be updated if that changes.
How to stay informed without guessing
If you want to track KPV's status honestly, the most reliable approach is to check back on this page or telos rx's dedicated KPV page. Forum chatter tends to run ahead of what is actually confirmed. Sellers outside licensed pharmacy channels sometimes imply availability that does not reflect any real regulatory clearance.
telos rx will update its own pages if KPV's status changes again, for example after FDA rulemaking. There is no subscription or notification list to join for this specific peptide.
How telos rx decides what to add
telos rx does not add a peptide just because its regulatory picture has improved. Each candidate goes through an internal review. It looks at the strength of available research, how consistently a compounding pharmacy can prepare it, and whether a provider can meaningfully screen a patient before approving it.
That process is deliberately slower than simply reacting to search volume or social media interest. A peptide can be widely discussed online and still not meet the bar telos rx sets for adding something to an active compounding program. KPV was in that position until its review was complete.
None of this is unique to KPV. The same review applies to every peptide telos rx considers, and some, such as GHK-Cu and epitalon, are still not offered.
What patients sometimes get wrong about "under review"
A common misunderstanding was treating "under review" as a soft promise of imminent release. It was not. telos rx used that phrase because it was accurate, not because it was a softer way of saying yes.
There was no internal launch date being withheld from this page. KPV was added only once its review was complete and the regulatory picture had changed, and this page was updated at that point rather than in advance.
What this means if you already use KPV informally
Some readers arrive at this page already sourcing KPV outside a licensed pharmacy. telos rx is not able to review, dose, or oversee anything obtained that way, and doing so carries real risk regardless of what any seller claims about purity or sourcing.
If you are currently using any unregulated peptide, telling your provider matters more than deciding whether to stop or continue. A provider can only give you meaningful guidance about interactions, dosing, or side effects if they know the full picture of what you are taking.
How telos rx's status pages stay current
telos rx reviews its research-peptide status pages on a recurring basis rather than leaving them static. That review checks for any change in regulatory classification, any update from internal compounding review, and any development worth reflecting here.
When a peptide's status changes, the update happens on the peptide's own page and on any related articles like this one. There is no separate mailing list for individual peptide updates, and telos rx does not send speculative notices about pending changes before they are confirmed.
Which is right for you
If you are interested in KPV, the KPV page explains how the online intake and provider review work. Your provider sets the dose, form and schedule, and approval is not guaranteed. For other goals, telos rx also offers BPC-157, PT-141, NAD+ nasal spray, and sermorelin.
Frequently Asked Questions
Does telos rx currently sell KPV?
Yes. KPV was previously not offered, but telos rx now prescribes compounded KPV after an online review by a licensed provider, who sets the dose, form and schedule. Approval is not guaranteed.
Is KPV coming to telos rx soon?
It is already offered. KPV moved from internal review to being offered after provider review. The KPV page explains how the online intake works.
Why wasn't KPV available earlier?
Demand alone does not determine what a compounding program offers. telos rx required KPV to complete internal review covering sourcing, classification, and provider oversight, and the regulatory picture also changed in October 2026.
Is KPV FDA-approved?
No. KPV is not FDA-approved, and compounded medications are not FDA-approved. The October 2026 HHS interim policy is enforcement discretion, not FDA approval.
What did the 2026 PCAC review actually decide about KPV?
In July 2026 the advisory committee voted to recommend adding KPV to the list of bulk substances for compounding. That vote was non-binding. On October 28, 2026, HHS announced a temporary enforcement discretion policy covering KPV in topical and oral forms only, while FDA completes rulemaking. It is not FDA approval.
What else does telos rx offer?
Alongside KPV, telos rx offers BPC-157, PT-141, NAD+ nasal spray, and sermorelin, all compounded through partner compounding pharmacies and reviewed by a licensed provider through an asynchronous intake.
telos rx is LegitScript-certified. Compounded medications are not FDA-approved and are prepared by partner compounding pharmacies under federal compounding regulations. KPV is offered by telos rx only after provider review, and the HHS interim policy for KPV covers topical and oral forms only. This article is general information, not medical advice, and does not replace guidance from your own provider. Approval for any compounded medication is subject to evaluation by a licensed provider, and approval is not guaranteed.
Questions about KPV? Visit the KPV page to see how the intake works.